Isaac Opoku-Asare
Cardiovascular Disease · Washington, DCNPI 1184887218
Payments from drug & device makers
What this record shows
This record is dominated by other: $120,000 of the $145,651 with a category attached, or 82.4%. Angiodynamics, Inc. accounts for 96.9% of it on its own, with 24 other manufacturers making up the rest. 2025 is the largest year on record at $30,380, 9.8 times the $3,101 reported in 2019. Among cardiovascular disease clinicians in DC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 94 payments — averaging $1549.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$141K
- Philips North America LLC$3K
- Boston Scientific$235
- Cardiovascular Systems Inc.$232
- Amgen$213
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$159
- plus $788 from 19 others
What the payments were for
- Travel & lodging$1,8551%
- Food & beverage$2,6662%
- Education$21,13115%
- Other$120,00082%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 8 | $141,177 |
| Philips North America LLC | 9 | $2,847 |
| Boston Scientific | 13 | $235 |
| Cardiovascular Systems Inc. | 7 | $232 |
| Amgen | 10 | $213 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $159 |
| Medtronic(2 entities) | 6 | $106 |
| Johnson & Johnson | 5 | $105 |
| Baxter Healthcare | 3 | $90 |
| Asahi Intecc USA, Inc. | 2 | $59 |
| Bard Peripheral Vascular, Inc. | 3 | $58 |
| Novartis | 3 | $54 |
| Abbott | 2 | $48 |
| Novo Nordisk | 2 | $39 |
| Actelion Pharmaceuticals US, Inc. | 1 | $34 |
| Reflow Medical Inc | 2 | $33 |
| Cordis US CORP. | 2 | $30 |
| Cardinal Health 200 LLC | 1 | $20 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $18 |
| Kestra Medical Technology Services, Inc. | 1 | $18 |
| Chiesi USA, Inc. | 1 | $17 |
| Biotronik Inc. | 1 | $16 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $16 |
| Pfizer | 1 | $14 |
| AstraZeneca | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auryon Laser System 100-120 Vac$141,083
- IGT D Peripheral$2,135
- IGT_D Systems$556
How this compares
$145,651 in reported general payments places this provider in the 95th percentile of 105 cardiovascular disease providers in District of Columbia.
See all cardiovascular disease providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 23 | $34,783 |
| EliquisApixaban | 32 | $28,432 |
| EntrestoSacubitril/Valsartan | 18 | $22,235 |
| Labetalol Hcl | 41 | $2,100 |
| Isosorbide Dinitrate | 22 | $1,782 |
| Nifedipine ErNifedipine | 33 | $1,667 |
| Metoprolol Succinate | 74 | $1,431 |
| Atorvastatin Calcium | 75 | $892 |
| ClopidogrelClopidogrel Bisulfate | 57 | $535 |
| Carvedilol | 20 | $302 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 19 | $289 |
| Hydralazine Hcl | 13 | $108 |
| Amlodipine Besylate | 39 | $105 |
| Losartan Potassium | 15 | $77 |
| Rosuvastatin Calcium | 11 | $56 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $105 | $34,78323 claims |
| PfizerEliquis | $14 | $28,43232 claims |
| NovartisEntresto | $54 | $22,23518 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 105 cardiovascular disease providers in District of Columbia.
Other cardiovascular disease in Washington
- Hayder HashimWashington$824K
- Joshua YamamotoWashington$376K
- Mardi Gomberg-MaitlandWashington$320K
- Jaffar KhanWashington$318K
- Judith HsiaWashington$65K
- Ana BaracWashington$34K
- Jonathan PlehnWashington$32K
- Andrew ChoiWashington$32K
- Felton AndersonWashington$23K
- Jose VargasWashington$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.